Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?

The aim of this study was to compare tumor expression of prognostic biomarkers between interval breast cancers and screen-detected breast cancers overall, and according to age at diagnosis and familial risk. Tissue micro-arrays were constructed from 98 breast cancers (47 interval and 51 screen-detected) diagnosed in women in the Cancer Genetics Network. Arrays were immuno-stained to compare protein expression of six biomarkers including estrogen and progesterone receptor (ER/PR), Her2/neu, EGFR, cytokeratin 5/6, and Ki67. Fisher’s Exact test was used to compare expression between interval and screen-detected cancers. Interval cancers were larger ( P = 0.04), higher stage ( P < 0.001), and more likely to have lobular histology ( P = 0.01) than screen-detected cancers. Overall, interval cancers more often overexpressed EGFR ( P = 0.01) and were somewhat more likely to be ER− (55% vs. 43%, P = 0.3), and triple negative (ER−/PR−/Her2−) (21 vs. 12%, P = 0.26). A greater difference in the proportion of interval versus screen-detected tumors that were ER− (53 vs. 35%; P = 0.29), PR− (35 vs. 21%; P = 0.25) and EGFR+ (17 vs. 0%; P = 0.02) was evident among women over 50. There was a trend toward differential expression among women with familial risk for PR− ( P = 0.005) and triple negative status ( P = 0.02). This study provides new data indicating that EGFR may be important in the etiology of interval cancer and be a possible therapeutic target. Our data also suggest that biological differences between interval and screen-detected cancers are more defined in older women. Future studies to confirm this finding and to elucidate novel markers for characterizing interval cancers may be more beneficial to this subgroup.